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Soluble epoxide hydrolase (sEH), an enzyme that broadly regulates the cardiovascular system, 
hydrolyses epoxyeicosatrienoic acids (EETs) to their corresponding dihydroxyeicosatrienoic acids 
(DHETs). We previously showed that endogenous lipid electrophiles adduct within the catalytic 
domain, inhibiting sEH to lower blood pressure in angiotensin II-induced hypertensive mice. As 
angiotensin II increases vascular H2O2, we explored sEH redox regulation by this oxidant and how 
this integrates with inhibition by lipid electrophiles to regulate vasotone. Kinetics analyses revealed 
that H2O2 not only increased the specific activity of sEH but increased its affinity for substrate and 
increased its catalytic efficiency. This oxidative activation was mediated by formation of an intra-
disulfide bond between C262 and C264, as determined by mass spectrometry and substantiated by 
biotin-phenylarsinate and thioredoxin-trapping mutant assays. C262S/264S sEH mutants were 
resistant to peroxide-induced activation, corroborating the disulfide-activation mechanism. The 
physiological impact of sEH redox state was determined in isolated arteries and the effect of the pro-
oxidant vasopressor angiotensin II on arterial sEH redox state and vasodilatory EETs indexed in 
mice. Angiotensin II induced the activating intra-disulfide in sEH, causing a decrease in plasma 
EET/DHET ratios that is consistent with the pressor response to this hormone. Although sEH C262-
C264 disulfide formation enhances hydrolysis of vasodilatory EETs, this modification also sensitized 
sEH to inhibition by lipid electrophiles. This explains why angiotensin II decreases EETs and 
increases blood pressure, but when lipid electrophiles are also present, that EETs are increased and 
blood pressure lowered. 




Soluble epoxide hydrolase (sEH) is distributed widely in tissues and is an important regulator of the 
cardiovascular system (1). This hydrolase is homodimeric with each monomer consisting of a C-
terminal domain with epoxide hydrolase activity and an N-terminal domain (NTD) with phosphatase 
activity (2, 3). The C-terminal domain catalyzes the hydrolysis of epoxides to their corresponding 
diols. Epoxy-fatty acids, such as epoxyeicosatrienoic acids (EETs), epoxydocosapentaenoic acids 
(EpDPEs), α- and γ-epoxyoctadecadienoic acids (α/γ-EpODEs) and epoxyoctadecaenoic acids 
(EpOMEs) are examples of endogenous substrates of sEH. Among these, EETs are the most 
studied and are known for their ability to induce vasodilation and decrease blood pressure (BP) (4-
8). sEH hydrolyses EETs to their corresponding diols, namely dihydroxyeicosatrienoic acids 
(DHETs), causing blood pressure to increase. Conversely, inhibition of sEH increases EETs that 
induce vasodilation, highlighting this enzyme as an important determinant of cardiovascular health 









smooth muscle proliferation (16). reduction of atherosclerosis and hypertension (13, 17-21), 
prevention and regression of cardiac hypertrophy, failure (22-24), and fibrosis (25). sEH is expressed 
in non-vascular tissues, with its inhibition limiting ischemic damage to the heart (26-31). brain and 
other organs (32, 33). Similarly, sEH null mice are protected from cardiovascular pathologies (28). 
On the other hand, genetic alterations that enhance sEH activity are a risk factor for human heart 
failure (22).  
 
sEH activity was considered to be controlled principally by its expression levels (34). However, we 
showed sEH activity is inhibited by electrophilic lipids, such as 15-deoxy-12,14-Prostaglandin J2 (15d-
PGJ2) or nitro-oleic acid (35-37). These endogenous lipid electrophiles bind and covalently adduct 
within the hydrolase C-terminal domain, inhibiting its catalytic activity to provide post-translational 
regulation of sEH.  
 
The abundance of EETs is commonly decreased in cardiovascular disease scenarios such as 
myocardial infarction, hypertension, and diabetes (22, 38, 39). and as mentioned above, 
polymorphisms that increase hydrolase activity cause heart failure. This decline in EETs is likely 
causal in the pathogenesis of these conditions, with sEH inhibitors that can increase epoxy-fatty 
acids providing therapy (40). Cardiovascular disease has been broadly linked, often causally, with 
oxidative stress. This is notable in the context of this study in which we describe a new mechanism 
of oxidative activation of sEH that would account for the loss of protective EETs.  
 
Given that hydrogen peroxide (H2O2) and lipid peroxides are ubiquitous and commonly mediate 
signalling to control physiological processes by modulating the redox state of proteins (41, 42). we 
determined their impact on sEH activity. We were intrigued to find that H2O2 oxidized and activated 
the hydrolase. Consequently, we investigated the molecular basis of this oxidative activation, tested 
if it occurred in cells and tissues and determined if there was a physiological manifestation of these 
events. The oxidative activation of sEH was caused by formation of an intra-disulfide bond between 
C262 and C264. Furthermore, angiotensin II, known for its ability to increase cellular H2O2 (43, 44), 
induced the formation of an activating intra-disulfide bond in mouse tissues, resulting in decreased 
plasma EET/DHET ratios. Thus, this new mechanism in which sEH is activated by oxidative intra-
disulfide bond formation,  may at least in part, contribute to the increase in blood pressure caused 
by angiotensin II. Formation of the disulfide also serves to sensitize sEH to inhibition by lipid 
electrophiles. This explains why angiotensin II decreases EETs and increases blood pressure, but 
in contrast, when lipid electrophiles are concomitantly present, EET levels are instead increased, 
and blood pressure lowered.  
 
 










Recombinant protein production 
The sEH full-length protein was cloned into pcDNA3.1D/V5-His-TOPO® vector (Invitrogen) as 
described earlier (45). It was expressed in HEK293-F cells and purified using Ni2+-IMAC as described 
earlier (45). Following successful purification, the protein fractions were pooled and the imidazole 
was removed using desalting spin columns (Zeba, ThermoFisher). The protein was then stored in 
50 mM Tris pH 7.5, 300 mM NaCl and then snap frozen in liquid N2 and stored at -80°C. Single 
mutants C262S, C264S, C262A and C264A were generated using the Quikchange II XL (Agilent) 
kit. Primers were designed using the Quikchange Primer Designer online tool. Successful 
mutagenesis was confirmed by sequencing (Eurofins MWG). The sEH mutants were expressed and 
purified as above as the WT protein. The sEH C-terminal domain was cloned as described 
earlier.(45) sEH C-terminal domain C264S mutant were obtained using the Q5® Site-Directed 
Mutagenesis Kit (NEB) and primers designed using the NEB Changer tool. sEH C-terminal domain 
WT and mutants were purified as described earlier (45) and stored at -80°C in the same buffer used 
for the full-length protein. Protein concentration was adjusted according to the theoretical molecular 
weight and extinction coefficient, obtained using the ProtPARAM ExPASY tool (46). 
 
In vitro sEH enzymatic assays  
Activity of WT and mutant sEH proteins were measured using a spectrofluorometric method (47). 
The assay uses the substrate 3-phenyl-cyano(6-methoxy-2-naphthalenyl) methyl ester-2-
oxiraneacetic acid (PHOME – Cayman), which is hydrolysed by sEH to generate a fluorescent end-
product, 6-methoxy-2-naphtaldehyde (6M2N). Specific activity of the recombinant enzymes was 
measured as described before.(45) Briefly, full-length protein and C-terminal domain enzymes were 
diluted with reaction buffer (25 mM TRIS-HCl pH 7.4) to respectively 322 nM and 8 µM, to be then 
mixed with 10 μM TCEP. For oxidation experiments, full-length protein and C-terminal domain 
enzymes were oxidized with a final concentration of 1, 10 or 100 µM H2O2 or tert-butyl hydroperoxide 
for 10 min at room temperature. A time course determined that a 10 minute pre-treatment with H2O2 
was optimal in terms of maximally stimulating the hydrolase, as shown in Supplementary Figure 1A. 
In specific activity measurements, the hydrolase was further diluted in reaction buffer in a black 96-
well polystyrene microtiter plate (ThermoFisher) to different final concentrations (full-length protein 
1, 2, 4, 5, 8, 10 nM; C-terminal domain 5, 10, 50, 100 and 200 nM), then PHOME (0.25 µM final 
concentration), freshly prepared in DMSO, was added to the 96-well plate. For Michaelis-Menten 
kinetic experiments, different substrate concentrations were aliquoted in a black 96-well plate (full-
length protein 0.25, 0.5, 1, 5, 10, 100 µM; C-terminal domain 0.25, 0.75, 1.5, 5, 10, 20 µM), to then 
add full-length protein and C-terminal domain enzymes at a final concentration of respectively 8 nM 
and 15 nM. Relative fluorescence (RFUs) was monitored at excitation 330 nm / emission 450 nm 
every min for 15 min using CLARIOstar plate reader (BMG Labtech) or a POLARstar Omega (BMG 









(45). IC50 measurements for both full-length protein and C-terminal domain proteins with 15d-PGJ2 
or AUDA were performed as detailed before (37), oxidation was induced with a final concentration 
of 1, 10 or 100 µM H2O2 or tert-butyl hydroperoxide for 10 min at room temperature, when required. 
The readout at 15 min was used to build the IC50 curve, fitted with “log(inhibitor) vs. response - 
variable slope” in GraphPad, and further considered exclusively if R2 was > 0.9. 
 
Quantification of the covalently modified sEH with biotin-15d-PGJ2  
To assess if oxidation affected electrophilic 15d-PGJ2 adducting to sEH, biotinylated-15d-PGJ2 
(Cayman) was used in an adaptation of the enzymatic assay method described above. Briefly, full-
length protein sEH protein was reduced with 10 µM TCEP on ice for 15 min, then diluted in freshly 
prepared 25 mM TRIS-HCl pH 7.4 to a final concentration of 322 nM. The proteins were then 
incubated at room temperature for 10 min with or without H2O2 (final concentration 1 µM), the proteins 
were then subsequently incubated at room temperature for 30 min with biotinylated-15d-PGJ2 (final 
concentration 10 µM). Protein samples were then re-suspended with an equal volume of 2x reducing 
Laemmli SDS sample buffer (total volume 100 µl). Protein samples were loaded and separated by 
SDS-PAGE using Mini-protean 3 system (Bio-Rad) and transferred to PVDF membranes (Bio-Rad). 
Blots were incubated with the biotin-antibody (#D5A7, Cell Signaling) diluted 1:1000 in PBS-Tween 
5% milk overnight. One hr of incubation with horseradish peroxidase-coupled anti-rabbit (#7074, Cell 
Signaling) IgG secondary antibody (diluted 1:1000 in PBS-Tween in 5% milk) was used to detect the 
primary antibody, along with ECL reagent (ThermoFisher). 
 
Cell sEH activity assays 
Cells treated with or without H2O2 were harvested and lysed in 0.5% digitonin lysis buffer and 
centrifuged at 3000 g for 5 min at 4 °C. sEH activity was measured with Cyano(6-methoxy-2-
napthalenyl)methyl[(2,3)-3-phenyloxiranyl]methyl ester, carbonic acid (Epoxy Fluor 7, Cayman) as a 
substrate. Total cell lysates were treated with or without AUDA to a final concentration 50 μM for 
15 min at 37 °C to determine the sEH contribution of Epoxy Fluor 7 hydrolysis. Subsequently 10 μM 
Epoxy Fluor 7 (final concentration) was added and fluorescence measurements made at excitation 
330 / emission 465 nm every 2 min for 1 h using a CLARIOstar plate reader (BMG Labtech) at 37 °C. 
Protein concentration were measured using the bicinchoninic acid assay. A standard curve using 
6M2N was used for quantification purposes.  
 
Liquid chromatography-tandem mass spectrometry 
100 µg of protein was dissolved in 70% formic acid prepared in UHQ Water. The protein was 
chemical digested following addition of a few crystals of Cyanogen Bromide (Sigma Aldrich, USA). 
The reaction was carried out at ambient temperature and in the dark for 5 hr and stopped with the 
addition of 2 mL of UHQ water. The sample was lyophilised and reconstituted in 100 µL of 50 mM 









Gold (Promega, USA) using a 1:50 enzyme:substrate ratio. The reaction was incubated at 37 C for 
5 hrs and halted by addition of formic acid to a final concentration of 0.5%. The digested samples 
were analysed using an Acquity H Class UPLC instrument, interfacing though an electrospray 
ionization (ESI) LockSpray source to a High Definition Mass Spectrometer Synapt G2Si qTof, both 
from Waters Corporation (Milford, MA, USA). Data were acquired using MassLynx v4.1 (Waters, MA, 
USA), and processed using UNIFI (Waters, MA, USA) 
The LC/ESI-MS was carried out using the following conditions: Column: Waters BEH300 C18 100 
mm x 2.1 mm, 1.7 µm, Column Temperature: 60 °C, Flow rate: 0.2 mL/min, Mobile Phase A: MS 
grade UHQ water, 0.1% Formic Acid, Mobile Phase B: MS grade Acetonitrile, 0.1% Formic Acid, 0-
2 min at 5% B, 2-40 to 43%B, 2 min to 80%B and at 80% for 3 min. The samples were acquired in 
MSe mode using a collision energy ramp from 25 to 45 eV.  
 
Quantification of epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids 
To extract oxylipins, epoxyeicosatrienoic acids (EETs) and dihydroxyeicosatrienoic acids (DiHETs), 
from plasma, a sample aliquot of 200 microliters was placed in a glass conical tube containing 
lyophilised antioxidants and deuterated internal standards. Antioxidants triphenylphosphine (TPP) 
and butylated hydroxytoluene (BTH) were added, each, at a final concentration of 0.2% v/v. EDTA 
was also added to a final concentration of 1% w/v. The internal standards, 14,15-EETd11 and 14,15-
diHETd11, were added at final concentrations of 50 ng/mL and 5 ng/mL, respectively, and desiccated 
prior to the addition of plasma. Each plasma sample was diluted with 300 µL of phosphate buffer pH 
7.8. Lipids were prepared using a Folch extraction by adding 2 mL of 2:1 Chloroform:Methanol to 
the diluted plasm, left at room temperature for 10 min, and vortexed vigorously at regular intervals. 
The organic phase containing the oxylipins was recovered by phase partition follow centrifugation 
and 1500 g for 10 min and was dried under a stream of nitrogen. 1 mL of 1 M NaOH was added to 
the dried lipid extract and incubated at 90 oC for 20 min. The solution was acidified with formic acid, 
and lipids were recovered with 4 mL of Ethyl Acetate. The organic phase separated by phase 
partitioning following centrifugation at 2500 g for 5 min, dried under a stream of nitrogen, and 
dissolved in a final volume of 50 µL of methanol.  
Separation of EETs and DiHETs was carried out by reverse phase using an Acquity H Class UPLC 
system (Waters Corporation, Milford, MA, USA), configured with a BEH300 C18,100 mm x 2.1 mm, 
1.7 µm column (Waters Corporation, Milford, MA, USA) with a constant flow rate of 0.4 mL/min. 
Column temperature was set at 40 °C. Mobile phases consisted of deionized water with 0.02% acetic 
acid (A) and acetonitrile (B). The initial condition set at 50%B ramped to 60%B in 0.1 min, and held 
for 1 min at 60%B, followed by a 2 min step gradient to 70% B, and again 3 min to 80% B. A negative 
ion mode was chosen in electrospray ionization mass spectrometry (ESI) for sample analysis. Data 
were acquired using the High Definition Mass Spectrometer (HDMS) Synapt G2Si qTof, (Waters 
Corporation, Milford, MA, USA), and MassLynx v4.1 acquisition software (Waters Corporation, 









Quantification of oxylipins was executed by MRM (multireaction monitoring) in negative ion mode 
using the following precursor ion > fragment ion transitions:  
5(6)EET (m/z 319.5>191.2), 5(6)DiHET (m/z 337.2>145.1), 8(9)EET m/z 319.2>155.1), 8(9)DiHET 
(m/z 337.2>127.1), 11(12)EET (m/z 319.2>167.1), 11(12)DiHET (m/z 337.2>167.1), 14(15)EET (m/z 
319.2>219.2), 14(15)DiHET (m/z 337.2>207.1), 14(15)EET-d11 (m/z 330.5>219.2), 14(15)DiHET-
d11 (m/z 348.6>207.1). 
EETs were quantified by linear regression analysis following the generation of a standard curve 
containing all EET analytes at concentrations ranging from 0.039 ng/mL to 50 ng/mL, and a fixed 
amount of EET d11, the internal standard, at a concentration of 50 ng/mL. Similarly, DiHET were 
quantified using a standard with calibrants in concentrations ranging from 0.039 pg/mL to 5 ng/mL, 
and the diHET d11 as an internal standard at a fixed concentration of 5 ng/mL.  
 
N-Biotinyl p-aminophenyl arsinic acid (Biotin-PAA) far western 
The bespoke synthesis of N-Biotinyl p-aminophenyl arsinic acid (Biotin-PAA) was commissioned to 
SynInnova Laboratories Inc. Recombinant protein was treated under control conditions, with H2O2 
(100 or 500 µM), 100 µM DTT or β-mercaptoethanol (5% v/v) for 15 min at room temperature. Protein 
samples were then re-suspended with an equal volume of 2x non-reducing SDS sample buffer. 
Protein samples were loaded and separated by SDS-PAGE using Mini-protean 3 system (Bio-Rad) 
and transferred to PVDF membranes (Bio-Rad). Membranes were blocked for 1 hr at RT in Dilution 
Buffer from Pierce™ Far-Western Biotinylated Protein:Protein Interaction Kit (Thermo Fisher). Biotin-
PAA was diluted to 0.4 mM in Dilution Buffer and incubated with the membrane for 1 hr at RT. The 
membrane was then washed 6 times with PBS-T and subsequently incubated with Streptavidin-HRP 
at 1:10,000. Protein bands were visualized on chemiluminescence film (GE Healthcare) following 
incubation of the membranes with ECL Western Blotting Detection Reagents (Pierce). 
 
C35A thioredoxin trapping mutant 
Modified pcDNA3.1+/C plasmids, containing a FLAG tag, with either WT thioredoxin or C35A 
thioredoxin trapping mutant were purchased from GeneScript. HEK cells were maintained in DMEM 
with 10% FCS and antibiotics. For treatment of HEK, cells were plated on to 12 well plates. HEK 
cells were transfected either with WT sEH DNA, C35A TRX DNA, C262A sEH DNA or doubly 
transfected either with WT sEH and C35A TRX DNA or C262A sEH and C35A TRX DNA using 
Lipofectamine 2000 (ThermoFisher) following the manufacturer’s instructions. 24 hr after 
transfection the cells were treated with or without auranofin (2.5 µM) for 30 min. Following treatment, 
the cells were lysed in immunoprecipitation buffer (100 mM Tris pH 7.4, 0.5 % Triton-X100, and 
supplemented with one complete mini EDTA-free protease inhibitor tablet) and subjected to FLAG 
immunoprecipitation. Briefly, the lysates were incubated with FLAG-agarose beads (Sigma) for 1 hr 
on a rotating wheel. After three washes with immunoprecipitation buffer the precipitates were re-









separated by SDS-PAGE (4-20% Mini-Protean TRX Precast Protein Gels, Bio-Rad) using Mini-
Protean 3 system (Bio-Rad) and transferred to PVDF membranes (Bio-Rad). Blots were incubated 
with the sEH antibody (#10010146, Cayman) diluted 1:1000 in PBS-Tween 5% milk overnight. One 
hr of incubation with horseradish peroxidase-coupled anti-rabbit (#7074, Cell Signaling) IgG 
secondary antibody (diluted 1:1000 in PBS-Tween in 5% milk) was used to detect the primary 
antibody, along with ECL reagent (ThermoFisher). 
 
Recombinant protein shifts 
100 ng recombinant protein (WT or C262A) was treated with H2O2 for 15 min, prior to the addition of 
non-reducing sample buffer. In some samples reducing agent, β-mercaptoethanol, was added. 
Protein samples were loaded and separated by SDS-PAGE (as described above), using 10% Mini- 
Protean TRX Precast Protein Gels (Bio-Rad) run at 90 V for 90 min. 
 
Angiotensin II treatment in mice 
All procedures were performed in accordance with the Home Office Guidance on the Operation of 
the Animals (Scientific Procedures) Act 1986 in UK and were approved by an institutional review 
committee. Mice were anesthetized and subjected to subcutaneous implantation of osmotic 
minipumps (model 1007D; Alzet) for delivery of angiotensin II (Sigma) at an infusion rate of 1 
mg/kg/day for 7 days. 
 
sEH activity in heart samples 
Hearts were rapidly isolated and frozen in liquid nitrogen at the end of the protocol. They were then 
powdered with a pestle and mortar under liquid nitrogen, which they were then stored in until further 
analysis. The hearts were homogenised (1 mL of buffer per 100 mg of cardiac tissue) on ice in 100 
mM Tris pH 7.4 supplemented with a complete mini EDTA-free protease inhibitor (Roche) using a 
Polytron tissue grinder. sEH activity was determined as described earlier (36).  
 
sEH quantification and molecular shifts in in vivo heart samples 
Powdered heart samples were homogenised (1 mL of buffer per 100 mg of cardiac tissue) on ice in 
100 mM Tris pH 7.4 supplemented with complete mini EDTA-free protease inhibitor (Roche) using 
a Polytron tissue grinder. Soluble fractions were prepared from the homogenate by adding Triton-
X100 to achieve a final concentration of 1% (v/v), with mixing and incubation on ice for 5 min prior 
to centrifugation at 25,000 g for 5 min at 4 °C. A sample of the homogenates were re-suspended in 
an equal volume of 2x non-reducing SDS sample buffer. In some samples reducing agent, β-
mercaptoethanol, was added to the sample buffer. Protein samples were loaded and separated by 











Thoracic aorta from mice were mounted in a Danish Myo Technology tension myograph, stretched 
to the optimal pretension condition with Danish Myo Technology normalization module and bathed 
in Krebs solution at 37 °C with a 95% O2:5% CO2 environment. Vasotone measurements were made 
after wake up with KCl (60 mM) by determining the responses of U46619-contracted (0.1 μM) to 
cumulatively increasing concentrations of 15d-PGJ2 or H2O2. In some experiments, vessels were 
pre-treated with 1 μM H2O2 for 30 min prior to the addition of 15d-PGJ2.  
 
AlloSigMA analysis 
AlloSigMA is a structure-based statistical mechanical model tool which calculates the per-residue 
allosteric free energies (Δgi) associated with residues perturbation. Per-residue Δgi > 0 and Δgi < 0 
correspond to increased and decreased free energies respectively, associated to allosteric signalling 
following a perturbation (48, 49). Our analysis was carried out on the AlloSigMA web-server (50) in 
probing map mode, perturbing C262 and C264 on the X-ray crystal structure of hsEH C-terminal 
domain (PDB entry code 6I5E) (37). The per-residue Δgi values above ± 1 standard deviation were 
reported on the hsEH protein structure in blue and red colour scales to indicate, respectively, 
stabilised and destabilised residues.  
 
PyMOL and MOLE analyses  
Using the sculpting tool in PyMOL Molecular Graphics System 2.0 (Schrödinger, LLC), a disulfide 
bond between C262 and C264 was modelled into the crystal structure of sEH (PDB entry number 
1S8O) (51). The results were analysed and visualised in PyMOL. Using MOLE 2.5, a toolkit for 
automated location and characterisation of protein cavities (52). the volume of the active site tunnel 
of oxidized and reduced sEH protein structures was measured. The analysis was performed using 
probe radius of 5 Å and an interior threshold of 1.1 Å.  
 
Michaelis-Menten modeling 
Using the kinetic data generated in experiments above and the Michaelis-Menten equation, we 
extrapolated these results and generated further data points over a wider range of substrate 
concentrations and plotted the data using Excel.  
 
COPA analysis 
COPA (Cysteine Oxidation Prediction Analysis) is a free internet software program accessible at 
http://copa.calstatela.edu. Through the analysis of the X-ray crystallography structure coordinates 
available in the Research Collaboratory for Structural Bioinformatics Proteins Data Bank (RCSB 
PDB), the software predicts cysteines susceptibility to the formation of disulphide bonds in non-
membrane proteins in solution (53). The analysis was herein performed on 26 randomly selected 
deposited X-ray crystallography structures of sEH (SI Table 1), all obtained in highly reducing 









Table 1: List of crystal coordinate used for the computational analysis in COPA. 
PDB  Reference  PDB  Reference  PDB  Reference  PDB  Reference  
1S8O  (51) 3I1Y  (54) 4HAI  (55) 3WK7  (56) 
1VJ5  (51) 3I28  (54) 4J03  (57) 3WK8  (56) 
1ZD2  (58) 3KOO  (59) 4JNC  (60) 3WK9  (56) 
1ZD3  (58) 3ANS  (61) 3WK4  (56) 3WKE  (56) 
1ZD4  (58) 3ANT  (61) 3WK5  (56) 3WKA  (56) 
1ZD5  (58) 3PDC  (62) 3WK6  (56) 3WKB  (56) 
3OTQ (63) 3WKC (56)       
 
Protein sequence alignments 
Primary sequence alignments of sEH were obtained with ClustalW multiple sequence alignment 
server (64) and alignment figures were generated using Jalview (65). 
 
Statistical analysis  
Results are presented as mean ± standard error of the mean (SEM). Differences between groups 
were assessed using analysis of variance (ANOVA) followed by a two-tailed unpaired Student’s t-
test or for multiple comparisons a Tukey’s post-hoc analysis. Results were considered significant 




sEH is activated upon exposure to H2O2 
H2O2 or tert-butyl peroxide significantly increased the specific activity of full length recombinant sEH 
in vitro (Figure 1A-B), enhancing its ability to hydrolyse epoxide substrates. However, the increased 
specific activity was not observed with 1 mM H2O2, which may be considered a supraphysiological 
concentration (Supplementary Figure 1B). Exposing a recombinant C-terminal domain fragment of 
sEH, the domain responsible for epoxy-fatty acid hydrolysis, to H2O2 similarly increased the specific 
activity of the hydrolase, recapitulating the oxidant-induced activation in the full-length enzyme 
(Supplementary Figure 1C). This is consistent with the increased hydrolase activity being 
predominantly, if not exclusively, linked to oxidative changes in the C-terminal domain. Pre-treatment 
of recombinant sEH protein in vitro with H2O2 or tert-butyl hydroperoxide also potentiated the 
inhibition induced by the physiological inhibitor 15d-PGJ2 (Figure 1C). Further analysis using biotin-
15d-PGJ2 revealed that more of this electrophile adducted to sEH when there had been a pre-
treatment with H2O2 (inset on Figure 1C). Analysis of full length sEH inhibition by 15d-PGJ2, with or 
without prior exposure to H2O2 or tert-butyl hydroperoxide, revealed a significant decrease of the half 









dose-dependent inhibition of sEH by 15d-PGJ2 was significantly leftward shifted when sEH was pre-
treated with either of the peroxide oxidants (Figure 1D-E). Thus, when the enzyme is oxidized, a 
lower concentration of the electrophilic inhibitor is required to obtain the same degree of hydrolase 
inhibition, indicating that these two mechanisms work synergistically. Essentially 15d-PGJ2 is a more 
potent inhibitor of oxidized than reduced sEH, an observation that was also made in separate studies 
with recombinant C-terminal domain protein (Supplementary Figure 1D). Interestingly, pre-
treatment of full length or C-terminal domain sEH with peroxide did not sensitize the hydrolase to 
inhibition by the synthetic inhibitor 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), indicating 
that the potentiation of inhibition might be linked to specific binding properties of 15d-PGJ2 (Figure 
1F-G and Supplementary Figure 1E).  
 
An intra-protein disulfide bond mediates hydrolase activation by H2O2 
We reasoned that the activation of sEH by peroxide molecules is likely mediated by the oxidative 
post-translational modification of one or more of the cysteines within the hydrolase domain. H2O2 
can react with protein thiols generating sulfenic acid, which, in turn, can be reduced by adjacent 
thiols, catalysing the formation of reversible intramolecular disulfide bonds.(66) We performed a 
bioinformatics analysis with the Cysteine Oxidation Prediction Algorithm (COPA) (67), screening 29 
X-ray crystallography structures of sEH previously reported in the RCSB PDB database. This 
revealed an average distance between C262 and C264 of 4.02 ± 0.10 Å and the algorithm predicted 
a high likelihood that this cysteine pair can form a disulfide (Supplementary Figure 1F).  
To investigate if a disulfide, as anticipated, forms under the oxidizing conditions and whether this 
activates the hydrolase, full length recombinant sEH was reduced with dithiothreitol (DTT) or oxidized 
by exposure to H2O2 or room air. These sEH preparations were individually chemically digested and 
analysed by liquid chromatography-tandem mass spectrometry. A peptide corresponding to the 
expected mass-to-charge ratio (m/z) of the peptide containing an intra-disulfide between C262 and 
C264 was observed in the samples exposed to air without DTT (expected m/z = 744.5994; observed 
m/z = 744.5991). The C262-C264 disulfide was confirmed by fragmentation of the peptide and 
identification of its b and y ions (Figure 2A). The oxidized peptide was not observed in the DTT-
treated sample (Figure 2B), indicating that the disulfide bond occurs as a consequence of oxidation 
and can be reduced by DTT. In samples treated with H2O2, two peptides with mass-to-charge ratios 
(m/z) that indicate the presence of an intra-disulfide between C262 and C264 were observed 
(Supplementary Figure 2A). These results conclusively demonstrate that a disulfide bond forms 
between C262 and C264 in sEH as a result of oxidation. 
To substantiate the COPA bioinformatics analysis and mass spectrometry findings that indicate sEH 
can form a disulfide, we performed an N-biotinyl p-aminophenyl arsinic acid (biotin-PAA) binding 
assay, applying this reporter compound to Western blots containing sEH exposed to reducing or 
oxidizing conditions. The PAA moiety selectively complexes with proteins with reduced, but not 









functionality enabling quantification of binding. Under reducing conditions with DTT or 
mercaptoethanol, when the vicinal cysteine thiols are in their reduced –SH form, biotin-PAA 
complexed with sEH and was detected using the western blot overlay method. In contrast, when 
sEH was air oxidized or exposed to H2O2, no signal was detected (Figure 2C, upper blot), consistent 
with oxidative intra-protein disulfide bond formation and adding support to the analysis by mass 
spectrometry. These samples were analysed on another gel probed with an antibody to sEH (Figure 
2C, lower blot), confirming that hydrolase protein was present in each sample, including those that 
did not generate a signal in the biotin-PAA assay. Notably, it became apparent that sEH migrated 
faster on the gel in the oxidized compared to the reduced form. It is well known that intra-disulfide 
bond formation can induce such downward gel shifts (66), providing a convenient readout of the 
thiol-disulfide redox state of sEH. To establish if the gel shift reflected the presence or absence of a 
C262-C264 intra-disulfide, we compared the gel migration of wild type (WT) sEH or C262A sEH, 
which cannot form the intra-disulfide, under H2O2 oxidizing or DTT reducing conditions. The 
downward gel shift induced by H2O2 in WT sEH was absent in the C262S mutant (Figure 2D-E), 
corroborating oxidation induces an intra-disulfide between C262 and C264 that causes a faster 
migrating band on non-reducing gels.  
 
Reduction of disulfide-sEH by thioredoxin in cells 
In the cellular context, proteins that are regulated by disulfides are typically returned to their reduced 
-SH state by the disulfide reductase thioredoxin (68). Thioredoxin uses two cysteine residues, 
namely C32 and C35, to catalyse the reduction of protein disulfide bonds. Thioredoxin C32 
undergoes a thiol-disulfide exchange with disulfide-containing targets proteins, becoming covalently 
conjoined by a disulfide bond. This association is transient as it is rapidly resolved by C35, generating 
a reduced target protein in exchange for oxidation of thioredoxin (68). C35A thioredoxin is unable to 
complete this reduction cycle and so becomes trapped on the disulfide-targets proteins that it 
attempts to reduce. We therefore expressed a C35A HA-thioredoxin-FLAG ‘trapping mutant’ in HEK 
cells expressing sEH. The affinity tagged thioredoxin allows its capture and the presence or absence 
of conjoined sEH to be determined. HEK cells expressing WT sEH or C262A sEH together with 
C35A thioredoxin were exposed to vehicle or auranofin, a thioredoxin reductase inhibitor that causes 
disulfide proteins to accumulate and increase their interaction with thioredoxin (69). WT sEH basally 
interacted with C35A thioredoxin and this was enhanced by treatment with auranofin, events that did 
not occur in cells expressing C262S sEH (Figure 2F-G). These data provide further evidence that 









and is recycled back to the reduced state by thioredoxin, which would return hydrolase activity to 
basal after oxidative activation.  
 
Impact of disulfide formation on sEH enzyme kinetics  
To characterise the impact of oxidation on increasing hydrolase activity, Michaelis-Menten kinetics 
analyses were performed, comparing the performance of full length recombinant sEH in the reduced 
or intra-protein disulfide state. H2O2 decreased the KM of sEH for substrate in a concentration-
dependant manner, with the maximum decrease being ~4-fold lower than in the reduced hydrolase 
(Figure 3A). This indicates that disulfide-sEH requires less substrate to reach half of the Vmax of the 
enzyme. The Ksp (kcat/KM) was also significantly increased, indicating that the catalytic efficiency of 
the enzyme was enhanced upon formation of the disulfide bond (Figure 3B). Oxidation decreased 
the Vmax, indicating the hydrolysis rate was decreased (Supplementary Figure 3A). Virtually 
identical results were obtained with the recombinant C-terminal domain protein, again consistent 
with oxidants enhancing activity by post-translationally modifying cysteines in this domain 
(Supplementary Figures 3C, D and E).  
Additionally, using the Michaelis-Menten kinetics curves determined in the experiments described 
above, we projected how the activity rate of sEH changes over a wide range of substrate 
concentrations (Supplementary Figure 3F). This analysis indicates that oxidation principally 
increases sEH activity (approximately 2.5-fold) at the lower substrate concentrations tested (inset on 
Supplementary Figure 3F). It is notable that these lower concentrations reflect those that occur 
physiologically (70). and importantly suggests that oxidation renders sEH capable of hydrolysing 
endogenous, basal levels of substrates that may otherwise be unable to metabolize efficiently.  
 
Cysteines 262 and 264 are required for oxidative activation of sEH 
Based on our findings above, the candidate cysteine residues C262 and C264 were mutated to 
serine to produce C262S or C264S mutant recombinant enzymes that were purified for activity 
analysis. The increased sEH activity observed in WT hydrolase upon H2O2 treatment was absent in 
both of the serine mutants (Figure 3C). WT or C262S or C264S sEH were also expressed in HEK 
cells, before exposure to vehicle or H2O2 and measuring the impact on hydrolase activity. Again, this 
demonstrated that the WT sEH activity was increased by H2O2 treatment, but was absent in both the 
serine and alanine mutants that cannot form the activating disulfide when exposed to oxidant (Figure 
3D-E). These observations are consistent with C262 and C264 being crucial to the peroxide induced 
activity increase. 
The significant decrease in KM in WT sEH induced by H2O2 was also absent in the C262S full-length 
mutant recombinant protein, though minor decreases in KM were observed for C264S mutated full-
length protein following H2O2 treatment, which were not significantly different (Figure 3A). There 
were no significant changes in Vmax in either C262S or C264S mutated full-length proteins following 









in the KM of the C262S sEH mutant following H2O2 treatment. An increase in Ksp for C264S (Figure 
3B) was observed, although negligible compared to the large increase induced in the WT by H2O2. 
When the C264 thiol was mutated to a non-reactive serine residue in the C-terminal domain 
preparation, no significant changes in either KM, Ksp or Vmax upon oxidation were observed 
(Supplementary Figure 3G, H and I), once again recapitulating the observations made with full-
length protein. Altogether, these findings are consistent with C262 and C264 being crucial to the 
peroxide-induced activity increase, through the formation of the intra-protein disulfide observed in 
our experiments. 
 
In silico analysis of disulfide bond formation in sEH 
To evaluate the effects of disulfide bond formation on the structure of human sEH we performed an 
AlloSigMA analysis. The software calculates the per-residue allosteric free energy variations (Δgi) 
as a consequence of a molecular perturbation, namely a disulfide in this case. In this analysis, 
residues showing an increase in Δgi are destabilised and exhibit increased dynamics, and vice versa 
when a decrease in Δgi is observed (48). This analysis indicated that the catalytic triad was largely 
unaffected by the formation of the disulfide bond, while the W334 niche of the active site becomes 
more rigid and the F267 pocket more dynamic (Figure 4). The magnitude of the observed Δgi values 
would indicate a likely conformational rearrangement of the amino acids forming the surface of the 
F267 pocket (Supplementary Figure 4A), which may presumably enable both substrate and 15d-
PGJ2 to accommodate better in the active site. This would account for the enhanced substrate 
hydrolysis, as well as the potentiated inhibition by 15d-PGJ2 when present, if sEH is oxidised to the 
disulfide state. We then mimicked a disulfide bond on the reduced X-ray crystallographic structure 
of human sEH (PDB entry number 1S8O) in PyMOL and used MOLE to measure the active site 
tunnel volume. This showed there was a general reduction in tunnel volume, from 5533 to 3529 Å3 
when the disulfide was present (Supplementary Figure 4B). Although our analysis is based only 
on local atomic geometries optimisation of the structure, this would agree with the AlloSigMA 
analysis that indicates that the enzyme undergoes a subtle conformational rearrangement that likely 
enhances the affinity for substrate and inhibitor. Surprisingly, the AlloSigMA analysis indicates a 
significant increase in the rigidity of the dimer interface (Figure 4).  
 
sEH activation in vivo contributes to angiotensin II mediated hypertension 
We hypothesised that angiotensin II may promote sEH oxidative activation in vivo because this 
vasopressor hormone increases endogenous H2O2 via oxidase activation (44, 71). There was a 
significant increase in sEH expression and activity in the myocardium of mice administered 
angiotensin II (Figure 5A-B). However, the increased activity after angiotensin II exposure was much 









consistent with another mechanism, namely the oxidative activation of sEH described herein, 
mediating the increased hydrolase activity.  
Consistent with increased sEH activity in mice exposed to angiotensin II, there was a significant 
decrease in 14,15-EET/DHET and 11,12-EET/DHET ratios in their plasma compared to those that 
received vehicle (Figure 5E-F). In contrast, no significant differences were observed in plasma 5,6- 
or 8,9-EET/DHET ratios (Figure 5G-H). We subsequently measured intra-protein disulfide levels in 
cardiac tissue of these mice using the non-reducing gel shift assay described above, which showed 
greater hydrolase oxidation in the angiotensin II group (Figure 5I-J). The finding that the vasopressor 
angiotensin II decreased vasodilatory EETs in plasma is causally consistent with the concomitant 
disulfide-dependant activation of sEH in these mice.  
To investigate this mechanism further, we treated isolated arteries with a low dose of H2O2. Aortas 
were chosen as a model artery because they do not dilate at the H2O2 concentration used to induce 
sEH oxidation, in fact at low doses of H2O2 aortas constrict (Figure 5K) (72). Whilst resistance 
arteries are more relevant to blood pressure control, they cannot be used with this protocol because 
they dilate efficiently to low concentrations of H2O2 alone (73). Aortas were pre-treated with H2O2 to 
induce the disulfide in the hydrolase, after which they were exposed to cumulatively increasing 
concentrations of the physiological sEH inhibitor 15d-PGJ2. This sEH inhibitor relaxes arteries 
because it increases the abundance of vasodilatory EETs (35). Low dose H2O2 induced a minor but 
statistically significant vasoconstriction as shown in Figure 5K. However, when this treatment was 
combined with 15d-PGJ2, there was a leftward shift in the concentration-response relaxation curve 
to this lipid (Figure 5L). Thus, H2O2-induced sensitization of the arterial relaxation to 15d-PGJ2 
manifests as a decreased IC50 (Figure 5M). So, despite starting off more constricted, the aortas 
dilated more to 15d-PGJ2 when pre-treated with H2O2.  
This is consistent with our biochemical findings above (Figure 1), whereby peroxide also decreased 
the IC50 for sEH inhibition by 15d-PGJ2. The intra-protein disulfide levels in aortas was determined 
following low dose H2O2 treatment by Western blotting. Again, there was a subtle but significant shift 
in the amount of oxidized sEH form as observed on the Western blot following peroxide treatment, 
indicating sEH formed the intra-protein disulfide ex vivo (Figure 5N).  
Overall, these results indicate that sEH activation by intra-protein disulfide bond contributes to 





Inhibiting sEH attenuates the hydrolytic loss of epoxy-fatty acids, including cyto-protective EETs (11, 
12, 20, 24). Consequently, an abundance of pharmacological inhibitors of sEH have been developed 
(74), with the rationale that they will increase epoxy-fatty acids levels to enable their beneficial 









dietary electrophilic lipids adduct to cysteine residues (35, 36), or peroxynitrite nitrates tyrosine 
residues (75).  
Here we report another mechanism of oxidative post-translational regulation in which H2O2 induces 
an intra-protein disulfide bond that activates the hydrolase to decrease EETs. We not only show and 
characterise this oxidative activation mechanism in detail using recombinant sEH in vitro and in cells, 
but also demonstrate that it operates in vivo in mice. The Graphical abstract provides a schematic 
overview of our findings. The observation that sEH can be activated by oxidants is especially notable 
given the huge investment in developing and testing inhibitors of this hydrolase for therapeutic 
purposes (76, 77). With these considerations in mind, a logical assertion is that the oxidative 
activation of sEH is likely to be maladaptive. In the context of cardiovascular disease, increasing 
sEH activity is considered detrimental and is attributed to loss of protective EETs (13, 20-22). Indeed, 
oxidative stress has routinely been implicated in the pathogenesis of hypertension. A common 
explanation for this is oxidative loss of nitric oxide; but the oxidative activation of sEH would provide 
an additional mechanism. Interestingly, a recent study showed bovine mastitis was associated with 
a concomitant increase in oxidants and sEH activity (22, 39, 78); consistent with the disulfide 
activation reported herein.  
Our results indicated that sEH activity was increased by oxidation induced by low physiological 
concentrations of H2O2. However, this effect was lost upon exposure to 1 mM H2O2, which instead 
caused some inhibition, as previously observed when similarly high concentrations of oxidants were 
assessed (79, 80). The bioinformatics analysis showed that C262 and C264 were highly conserved 
in the phylogenetic tree from Xenopus tropicalis to Homo sapiens. Interestingly, the amino acids 
around these cysteines also showed a high degree of homology, consistent with C262 and C264 
having important roles in the maintenance of structure or function of sEH, including in humans. 
Overall, our data indicated that sEH oxidation induced a disulfide bond between C262 and C264. 
This post-translational modification significantly increased the specific activity and catalytic efficiency 
of sEH. Our detailed enzymology analysis collectively indicated that oxidation to the disulfide state 
allows sEH to hydrolytically transform more substrate into product per unit time. Mutation of C262 to 
serine abrogated the oxidative activation and changes in KM and Ksp observed in WT sEH on 
exposure to H2O2. However, the C264S mutant showed an insignificant trend for the KM to be 
decreased and the C264S Ksp was significantly increased after H2O2 treatment. These alterations in 
hydrolase performance after exposure to H2O2 are minor compared to those in WT and may be 
because C262 is more oxidant reactive than C264. In this scenario, C262 may react with H2O2 to 
stepwise form a sulfenic acid, which can be further oxidized to sulfinic or sulfonic acid, events that 
would potentially explain these minor changes in enzyme kinetics. Interestingly, the Vmax following 
oxidation also decreased (Supplementary Figures 3A, E, & I), most likely reflecting an increased 
retention time of the hydrolysis product in the active site of the enzyme. One could envisage that a 
side chain rearrangement upon oxidation suggested by our molecular modelling data might improve 









with an improved substrate accommodation in the proximity of the catalytic triad, overcomes the 
reduced enzymatic turnover and leads to an overall increase in specific activity and catalytic 
efficiency (Ksp). Using the Michaelis-Menten constants determined for WT sEH, we determined the 
impact of oxidation on hydrolysis of its substrates at different concentrations as shown in 
Supplementary Figure 5. This analysis illustrates when substrate concentration is below ~1.6 
µmol/L, which is typical in biological systems (70), that the impact of oxidation is to increase epoxide 
hydrolysis.  Hence, oxidation to the intra-protein disulfide is a switch that enables sEH to hydrolyse 
EETs at the levels they occur basally. Although these conclusions are based on studies with the 
synthetic substrate PHOME, Gomez et al. concluded that its hydrolysis is mechanistically similar (i.e. 
alkyl-enzyme intermediate followed by hydrolytic release) to that of physiological epoxy-fatty acids 
(58). Thus, the effects of sEH oxidation observed are likely to be recapitulated for the catalysis of 
biologically relevant substrates. Nevertheless, by lowering the KM for substrate by inducing the 
disulfide, oxidants bring EETs within ‘range’ of the hydrolase. Indeed, in mice exposed to pro-oxidant 
angiotensin II, in which disulfide-sEH accumulates, there was a decrease in the EETs/DHETs ratio, 
consistent with the increased sEH activity.  
Analysis using AlloSigMA revealed that the intra-protein disulfide bond between C262 and C264 
induce a conformational rearrangement of the amino acids that form the surface of the so-called 
F267 pocket, one of the two sides of the hydrophobic tunnel where the enzyme active site resides. 
In addition, our data generated with PyMOL and MOLE are consistent with a noticeable narrowing 
of the F267 pocket when the C262-C264 disulfide bond is present. Overall, this would suggest that 
the substrate can be stabilised in the active site, optimising its hydrolysis and, thus, increasing the 
enzyme specific activity. Our previous study showed that the F267 can also accommodate the 
electrophilic lipid 15d-PGJ2 before it adducts the cysteine residues C521 and C423, inhibiting the 
enzyme (37). Our modeling would then suggest that, upon formation of the disulfide bond, the 15d-
PGJ2 would also bind tighter in this region of the active site, exerting a more effective inhibition as 
herein observed. Also, this would increase its residency time in the active site and allow a more 
effective covalent adduction, as here reported.  
The finding that thioredoxin reduces disulfide-sEH back to the reduced –SH state in cells means that 
basal hydrolase activity can be recovered in a regulated manner after oxidative activation. sEH was 
identified as a substrate for thioredoxin previously (81), again consistent with the disulfide being 
reversible. However, crystal structures of sEH indicates that the disulfide between C262 and C264 
is not on the surface of the protein and so precisely how thioredoxin reduces the disulfide remains 
unclear. Thioredoxin can reduce buried disulfide bonds in arsenate reductase with the involvement 
of additional cysteine residues (82), so it is feasible that thioredoxin could do the same to the disulfide 
in sEH. Confidence that thioredoxin truly reduces the C262-C264 disulfide comes from the fact that 
C262S sEH was not significantly captured by the trap mutant. In addition, cells exposed to auranofin 
to inhibit thioredoxin reductase and limit thioredoxin-dependant substrate reduction caused more 









We investigated if C262-C264 disulfide-sEH formed in vivo and if so whether oxidation event 
mediated a physiological effect. Angiotensin II is a pro-oxidant peptide hormone that causes arterial 
constriction, elevating blood pressure in animals and humans (83), it also stimulates NADPH 
oxidases, producing superoxide and H2O2 (43, 84, 85). Consequently, we speculated that 
angiotensin II may therefore indirectly induce a disulfide bond in sEH, activating the hydrolase. 
Indeed, angiotensin II induced a disulfide bond within sEH, and increased its activity. These 
observations are consistent with our biochemical findings in which recombinant sEH in vitro or in 
cells is activated by oxidation.  
EETs were decreased in mice exposed to angiotensin II or in models of ischemia-reperfusion, 
scenarios where oxidant levels are also increased (13, 21, 86, 87), consistent with our findings that 
oxidation induces activation of sEH. EETs offer several cardiovascular benefits, including reducing 
blood pressure, attenuating ischemic damage and modulating inflammatory responses. Therefore, 
an increase in sEH activity due to disulfide bond formation will limit the protective cardiovascular 
effects of the EETs. Inhibition of sEH offers cardiovascular protection in a variety of different disease 
scenarios (21, 88), which is consistent with oxidative activation of the hydrolase causally contributing 
to the pathogenesis of these disease states. In this connection, there are a number of human single-
nucleotide polymorphisms (SNPs) in sEH that enhance hydrolase activity and are risk factors for 
human heart failure (89). Interestingly, the human polymorphism R287Q is capable of disrupting the 
enzyme dimerization, and reducing in vitro epoxy-hydrolytic activity (90). Perhaps enhanced rigidity 
at the dimerization interface induced by the disulfide bond between C262 and C264, as our 
AlloSigMA analysis indicated may occur, stabilises the dimer in solution to increase hydrolase 
activity. 
The plasma of angiotensin II treated mice showed significantly decreased 14,15- EET/DHET and 
11,12-EET/DHET ratios, consistent with C262-C264 disulfide activation of sEH enhancing hydrolysis 
of EETs. Interestingly, sEH activation and increased DHET abundance was observed in HEK cells 
during nitrosative stress and was attributed to S-nitrosation of C264 (38). This is notable, as we have 
previously shown that S-nitrosated proteins generically transition to disulfide bond formation (91), 
hence it is likely that the S-nitrosation of C264 induced the activating intra disulfide with C264. In 
contrast to the increase in 14,15- EET/DHET and 11,12-EET/DHET during angiotensin II treatment, 
the 8,9- or 5,6-EET/DHET ratios were not altered. sEH has some selectivity towards different EET 
regioisomers, with 14,15-EET being its preferred substrate, followed by 11,12- and 8,9-EET, with 
5,6-EET being considered a poor sEH substrate (92). Of course, formation of the disulfide may 
changes this substrate selectivity and could account for the 8,9- or 5,6-EET/DHET ratios not 
changing. Although there are well-established mechanisms of angiotensin II-induced hypertension 
(93), our observations are consistent with oxidant-induced sEH activation also plays a causal role, 
although it  is difficult to determine the relative contribution of the various mechanisms.  
Our observations not only demonstrate that disulfide formation enhances sEH activity, but also 









These results are consistent with the peroxide-induced disulfide causing a conformational change 
that both enhances utilization of substrates as well as inhibition by 15d-PGJ2, consistent with the 
structural modeling outlined above. Interestingly, peroxide-induced sensitization was not observed 
with the inhibitor AUDA. Although a crystal structure of sEH with AUDA bound is not available, the 
interaction of this inhibitor within the active site may be unaffected by the disulfide, based on its 
physico-chemical properties. This oxidant-induced sensitization to inhibition by 15d-PGJ2 was 
recapitulated in isolated arteries, whereby low dose H2O2 pre-treatment enhanced arterial 
vasodilation to 15d-PGJ2. Thus, despite arteries being slightly more constricted after pre-treatment 
with low dose H2O2, which could be due to disulfide activation of sEH, their subsequent dilatory 
responses to 15d-PGJ2 were enhanced compared to those without the initial exposure to oxidant.  
In conclusion, sEH activity is redox regulated by the presence or absence of an intra-disulfide bond. 
Oxidants such as H2O2 induce a C262-C264 intra-disulfide that increases hydrolysis of vasodilatory 
EETs to cause vasoconstriction and increase blood pressure. Formation of the disulfide lowers the 
KM of sEH for its substrates, enabling efficient hydrolysis of the basal levels of EETs. This disulfide-
activation mechanism, which occurs in vivo in response to the pro-oxidant angiotensin II, may in part 
account for the pressor effect of this hormone. Formation of the disulfide also serves to sensitize 
sEH to inhibition by lipid electrophile if they are present. This explains why angiotensin II decreases 
EETs and increases blood pressure, but when lipid electrophiles are present, EET levels are instead 
increased and blood pressure lowered. It is conceivable that people who consume a Mediterranean 
diet, which supplies lipid electrophiles, maintain a normal blood pressure during oxidative stress 
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Figure 1. The effect of peroxide treatment on sEH activity. (A) H2O2 increased sEH activity as 
did (B) tert-Butyl peroxide. (C) H2O2 potentiated 15d-PGJ2-dependent inhibition of sEH. H2O2 also 
potentiated adduction of 15d-PGJ2 to sEH as measured by incorporation of a biotin-labelled 
analogue detected by Western blotting. This potentiation was absent with the par excellence sEH 
inhibitor, AUDA. Data was normalised to percentage of control. (D-E) IC50 for 15d-PGJ2-dependent 
inhibition of hydrolase activity with or without peroxide treatment. Data was normalised to percentage 
of control. (F-G) IC50 for AUDA-dependent inhibition of hydrolase activity with or without peroxide 














Figure 2. sEH oxidation results in the formation of a disulfide bond. (A) An LC-MS/MS spectra 
identifying a peptide with an m/z of 744.59914+ (-0.4 ppm) was assigned to the peptide 
250LHFVELGSGPAVCLCHGFPESWYSWR275 in the air oxidized protein samples. A disulfide bond 
was detected between the two cysteine residues, C262 and C264, as shown in red. The peptide was 
confidently assigned through the identification of its b and y ions as shown. (B) A peptide with an 









248VRLHFVELGSGPAVCLCHGFPESWYSWR275,  indicating the absence of a disulfide bond as is 
anticipated when the reductant DTT was present. (C) Analysis with biotin-PAA confirmed disulfide 
bond formation via vicinal thiols within purified recombinant sEH. Following peroxide treatment, 
biotin-PAA was unable to adduct to sEH, however in reduced samples a band corresponding to sEH 
was observed when probed with streptavidin-HRP. Western blot below showing that WT sEH protein 
was present in all lanes following biotin-PAA treatment. This non-reducing blot also showed there 
was a downwards band shift in sEH when it was exposed to oxidizing conditions. (D-E) In separate 
experiments, recombinant sEH protein samples, which had been exposed to reducing or oxidizing 
conditions, were probed to monitor for the downwards band shift in sEH. There was a downwards 
band shift in WT sEH after oxidant exposure, consistent with disulfide formation. In contrast, C262S 
sEH did not as it does not have the thiols needed to form the disulfide that mediates the shift. (F) A 
C35A Trx trapping mutant was used to identify proteins that form disulfide bonds. Western blot 
indicating there was equal amounts of sEH in the input for the immunoprecipitation. (G) Western blot 
showing sEH immunoprecipitated from C35A Trx tapping mutant. Following auranofin treatment, a 
significant amount of WT sEH was captured by the C35A Trx trapping mutant. However, when 













Figure 3. Enzymatic analysis of sEH. (A) H2O2 treatment reduced the KM of purified recombinant 
WT sEH, indicating an increased affinity for substrate upon oxidation. No significant changes in KM 
was observed for the C262S mutated purified recombinant protein following H2O2 treatment. A minor 
decrease in KM was observed for the C264S mutated purified recombinant protein following H2O2 
treatment, which was not significantly different. (B) An increase in Ksp of recombinant WT sEH was 
observed following H2O2 treatment, indicating an enhanced catalytic efficiency upon oxidation. There 
was no change in catalytic efficiency (Ksp) of C262S following H2O2 treatment, however in C264S 
sEH the Ksp was a minor increase. (C) The mutation of the thiol moieties of C262 and C264 into non-
reactive serine residues abrogated the significant increase in specific activity that was observed with 
WT sEH recombinant enzyme. Data were normalised to percentage of control. (D-E) WT sEH, 
C262S, C264S, C262A or C264A proteins were overexpressed in HEK cells and their sEH activity 
was assessed with or without exposure to H2O2. There was a significant increase in WT sEH activity 
following H2O2 treatment, which was not observed in cells expressing any of the mutated proteins. 













Figure 4. hsEH oxidation might induce conformational rearrangements. (A) sEH is a dimer with 
a swapped-domain architecture, where the C-terminal domain of one subunit interacts with both the 
C-terminal domain and the NTD of the other monomeric unit. (B) The panel reports the cartoon 
representation of the structure of hsEH C-terminal domain and its 170° rotation. The ‘L-shaped’ 
active site is depicted in surface mode. The F267 pocket, vertex and W334 niche are coloured 
respectively in magenta, blue and cyan. The cysteine residues involved in the disulfide bond are 
reported as orange sticks. The residues of the dimerization interface are depicted by green sticks. 
(C) AlloSigMA analysis of the perturbation of C262 and C264. The panel shows a cartoon model of 
sEH C-terminal domain (same orientations as in B), coloured according to the predicted Δgi. The 













Figure 5. In vivo assessment of novel intra-protein disulfide in sEH. (A) Reducing Western blots 
showing that angiotensin II induced sEH expression over 7 days. The lower GAPDH blot confirms 
equal protein loading. (B) Angiotensin II treatment significantly increased sEH expression in mouse 









Correcting hydrolase activity for the increased sEH protein content revealed that hydrolase activity 
was still significantly increased, consistent with oxidant-induced activation of the hydrolase. (E-H) 
There was a significant decrease in the EET/DHET ratio for 14,15-EET/DHET and 11,12-EET/DHET 
as compared to saline treatment. No significant differences were observed for the 8,9- or 5,6-
EET/DHET ratios. (I-J) Non-reducing blot showing there was a downward band shift in sEH in the 
hearts from angiotensin II treated mice, with quantification shown below, consistent with oxidant–
induced disulfide formation. (K) H2O2 induced constriction of mouse aortas, consistent with sEH 
activation. (L-M) H2O2 pre-treatment potentiated 15d-PGJ2-induced arterial dilation, as indicated by 
the dose-response curve being shifted to the left as compared to the 15d-PGJ2 alone and by the 
decreased EC50. (N) Mouse aortas were assessed for intra-protein disulfide bond formation 
following peroxide treatment. There was a subtle downwards shift to the faster migrating oxidized 
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